SciSparc will earn royalties from the commercialisation of the pain therapy. Credit: Wasan Tita/Shutterstock.

Israel-based pharmaceutical company SciSparc has signed an exclusive patent licence agreement with Polyrizon to out-license its SCI-160 programme for pain treatment.

Polyrizon will receive a sole, royalty-bearing worldwide licence for developing and sublicensing the assets.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In return, SciSparc is entitled to receive Polyrizon securities valued at $3m, along with potential milestone cash payments of $3m, contingent upon achieving specific development goals.

SciSparc will earn royalties from the commercialisation of the therapy.

SCI-160 is a synthetic combination of cannabinoids and N-acyl ethanolamines which has been shown to mediate analgesic effects in the peripheral nervous system.

This occurs without causing significant side effects in both acute and chronic pain models.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pre-clinical studies conducted by SciSparc have identified several proprietary combinations with analgesic properties.

SCI-160 demonstrated a favourable safety profile, showing no significant adverse clinical effects.

In some studies, it matched the analgesic effect of high-dose morphine and, in certain cases, proved even more potent.

The development of SCI-160 comes amid concerns over opioid abuse, which the Centers for Disease Control and Prevention have identified as a significant public health issue.

SciSparc CEO Oz Adler stated: “We are pleased to finalise the licence agreement for the out-licensing of the SCI-160 programme for treating pain. The licence agreement may allow us to enjoy royalties and milestones payments from the SCI-160 programme without investing additional funds in the development.”

In July 2024, SciSparc announced a non-binding letter of intent to spin off its cliniclinical-stagemaceutical portfolio and its equity stake in SciSparc Nutraceuticals.

The letter of intent refers to a proposed asset and share purchase agreement with Miza III Ventures in Canada, with the definitive agreement yet to be negotiated.